Evidence map›Paper›PMID 30937169›Full record

ArticleSAGE open medicine2019

Rescue treatment in patients with poorly responsive Guillain-Barre syndrome.

Ayman Mahmoud Alboudi, Pournamy Sarathchandran, Samar Sameer Geblawi, Deeb Maxwell Kayed, Jihad Inshasi, Sadhik Puthan Purayil, Abu Baker Almadani, Bashar Katirji

Abstract read
In one paragraph

Article in SAGE open medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ayman Mahmoud AlboudiNeurology Department, Mercy Health Saint Mary Hospiatal, Grand Rapids, Michigan, US.ORCID https://orcid.org/0000-0003-3091-0868
Pournamy SarathchandranNeurology Department, Rashid Hospital, Dubai, UAE.
Samar Sameer GeblawiPediatrics Department, Latifa Hospital, Dubai, UAE.
Deeb Maxwell KayedDepartment of Neurology, Mediclinic City Hospital, Dubai, UAE.
Jihad InshasiNeurology Department, Rashid Hospital, Dubai, UAE.
Sadhik Puthan PurayilNeurophysiology Division, Neurology Department, Rashid Hospital, Dubai, UAE.
Abu Baker AlmadaniNeurology Department, Rashid Hospital, Dubai, UAE.
Bashar KatirjiUniversity Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the effectiveness of rescue treatment (intravenous immunoglobulin or plasma exchange) in patients with Guillain-Barre syndrome who did not respond or deteriorated after the initial management with intravenous immunoglobulin.

methodsWe performed a retrospective review of the medical records of patients who responded poorly or did not respond to intravenous immunoglobulin treatment. The disability parameters of those who received second-line treatment with intravenous immunoglobulin or plasma exchange (20 patients) were compared with those who did not receive second-line treatment (19 patients).

resultsThere was a statistically significant improvement in disability scores at 1 month in the patients who received the rescue treatment (p = 0.033). However, there was no significant difference in the disability scores at 3 and 6 months, or in length of intensive care unit stay.

conclusionOur study showed that a second course of treatment to carefully selected patients may be beneficial.

Indexed as

Guillain–Barreintravenous immunoglobulinplasma changesrescue treatment

Identifiers

PMID30937169
PMCPMC6434439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.